CCP
TXG icon

Cardan Capital Partners’s 10x Genomics TXG Stock Holding History

Cardan Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.93M Hold
13,260
– – 0.22% 102
2021
Q2 		$2.6M Buy
+13,260
New +$2.4M 0.29% 100

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cardan Capital Partners's TXG Position: Q3 2021 in Review

Cardan Capital Partners held its 10x Genomics (TXG) position steady in Q3 2021 at 13,260 shares worth $1.93M. The position accounts for 0.22% of the portfolio, ranked #102.

Cardan Capital Partners first reported a position in TXG in Q2 2021 and has held it in 2 quarters since. The position peaked at $2.6M in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

  • Cardan Capital Partners held 13,260 shares of 10x Genomics worth $1.93M as of Q3 2021.
  • Cardan Capital Partners left its 10x Genomics share count unchanged in Q3 2021.
  • 10x Genomics made up 0.22% of Cardan Capital Partners's portfolio in Q3 2021, its #102 holding.
  • Cardan Capital Partners first reported a position in 10x Genomics in Q2 2021 and has held it in 2 quarters since.
  • Cardan Capital Partners's 10x Genomics position peaked at $2.6M in Q2 2021.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on Cardan Capital Partners's 13F filing for Q3 2021, filed 25 Oct 2021.